NAL is focused on commercialising leading edge technology such as laser assisted drug delivery devices and immunology technology. The company has placed initial orders for the production of its device and expects to generate high margin revenue on the sale of disposable accessories. NAL's immunology technology will enter clinical trials in 2004 ahead of FDA approval expected afterwards. This will trigger milestone payments and subsequent royalty payments should trial results prove successful. We expect a strong market response to this technology and value NAL at $2.53 per share.
I especially love their timing!
- Forums
- ASX - By Stock
- NAL
- great notice on shawonline
great notice on shawonline
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online